Table 2

Objective response and disease control rate (per iRANO) in the study population

Overall population
(n=54)
Cohort-1
(n=27)
Cohort-2
(n=27)
Confirmed objective response, n(%)15 (27.8%)9 (33.3%)6 (22.2%)
Complete response2 (3.7%)1 (3.7%)1 (3.7%)
Partial response13 (24.1%)8 (29.6%)5 (18.5%)
Stable disease, n(%)15 (27.8%)8 (29.6%)7 (25.9%)
Progressive disease, n(%)24 (44.4%)10 (37.0%)14 (51.9%)
Disease control rate, n(%)30 (55.6%)17 (63.0%)13 (48.1%)
Median duration of response, weeks18.0
(range 6.0–83.1)
17.9
(range 6.0–83.1)
19.0
(range 8.0–38.0)
Median time to response, weeks6.0 (range 4.7–18.0)6.0 (range 5.1–18.0)5.9 (range 4.7–8.0)
  • iRANO, immunotherapy response assessment for neuro-oncology.